A Study of Diabetes Associated Oral Manifestations

The over-expression of miRNA-206 in peripheral blood of patients with burning mouth syndrome and its relationship with anxiety and depression

BACKGROUND

Burning mouth syndrome (BMS) is characterised by persisting burning pain of the oral mucosa, and its etiopathogenesis remains poorly understood.

OBJECTIVES

Our study aimed to detect the expression of miRNA-206 in the blood and clarify the relationship among miRNA-206, pain, anxiety and depression of BMS patients.

METHODS

Thirty patients with BMS and 30 healthy individuals were enrolled in the experimental and control groups, respectively. Data on medical history and clinical oral examination for all participants were collected. Simultaneously, scores of Visual Analogous Scale (VAS), Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) were administered. The expression level of miRNA-206 in plasma were determined by RT-(q)PCR. Finally, the relationship of miRNA-206 expression with the VAS score, SAS score, and SDS score was analysed. Chi-square test and t-test were used for statistical analysis of the data, and p < .05 was considered statistically significant.

RESULTS

The majority of the patients with BMS identified the tongue as the main pain area, and showed dry mouth and poor sleep quality. The SAS and SDS scores of patients with BMS were higher than those of healthy controls (p < .05) and were positively correlated with VAS pain score. In addition, miRNA-206 expression was higher in patients with BMS than in healthy individuals (p < .05), and was positively correlated with the VAS and SDS scores (p < .05).

CONCLUSIONS

Patients with BMS suffer from pain and tend to be more anxious and depressed than healthy controls. miRNA-206 expression in the peripheral blood of patients with BMS is positively correlated with pain and depression, which may be involved in the pathogenesis of BMS.

Evaluation of gingival and periodontal status in obese and non-obese type II diabetic patients - a cross sectional study

Objective

The aim of this study was to evaluate gingival and periodontal status in obese and non-obese type II Diabetic Patients.

Methods

The study population comprised of 75 subjects visiting the outpatient department of our institution, divided into three different groups, group 1 (obese diabetic), group 2 (non-obese diabetic), and group 3 (obese, non-diabetic). Diabetic status was assessed with HbA1c values and obesity status was assessed by body mass index (BMI) score greater than or equal to 30 kg/m². Gingival and periodontal status were assessed using the Gingival Index (GI) and Community Periodontal Index (CPI) respectively.

Results

The mean gingival index score in group 1, group 2, and group 3 were 1.58, 1.54, and 1.25, respectively. Gingival status was poor among obese and non-obese diabetic subjects (Groups 1 and 2) when compared with obese non-diabetic patients (Group 3). The periodontal status showed that periodontal pockets were increased in diabetic obese group (15.4%), followed by diabetic non obese (4.66%), and non-diabetic obese (2%) group respectively and loss of attachment was severe in diabetic obese group (60.7%), followed by diabetic non obese (45.9%) and non-diabetic obese (15.3%) respectively.

Conclusion

Gingival and periodontal status was poor in the obese diabetic group compared to non-obese diabetic and obese non diabetic group. Hence, the risk of gingivitis and periodontitis in obese diabetic patients should be addressed earlier to prevent further complications and achieve a good oral health status.

Quantification of TNF-α in Patients with Periodontitis and Type 2 Diabetes

OBJECTIVE

The present study aimed to compare variations in quantified tumor necrosis factor-alpha (TNF-α) levels in patients with periodontitis stage 2 grade B (POD2B) and/or type 2 diabetes (T2D) and to identify any relationships between this cytokine and these diseases.

METHODS

Levels of the cytokine TNF-α in gingival crevicular fluid in patients with POD2B and/or T2D were evaluated. A total of 160 subjects were distributed into four groups: those with POD2B (n=44); those with T2D (n=37); those with POD2B/T2D (n=40); and healthy subjects (n=39). Glycosylated hemoglobin (HbA1c) and blood glucose (BG) levels were quantified in each subject. Data were collected on body mass index (BMI), loss of insertion (LI), and probe depth (PD). Gingival crevicular fluid samples were collected from the most acutely affected periodontal pocket and gingival sulcus in each subject, and TNF-α was quantified by multiplex analysis.

RESULTS

Kruskal Wallis tests was used to identify differences in TNF-α levels, LI, PD, BMI, BG, and HbA1c by group. Differences (p<0.001) were found for LI, PD, BG, and HbA1c. A Spearman test was used to calculate possible correlations between TNF-α levels and LI or PD identified a weak but significant negative correlation of TNF-α with LI (Rho=-0199; p=0.012), and a moderately positive correlation of LI with PD (Rho=0.509; p < 0.001).

CONCLUSIONS

No variation was found between TNF-α levels and the presence of POD2B, POD2B/T2D, or T2D, suggesting the absence of any direct relationship between progression of these diseases and TNF-α levels. However, a correlation was present between low TNF-α concentrations and greater LI.

Antidiabetic Activity of Ajwain Oil in Different In Vitro Models

Context:

Ajwain oil is an essential oil with thymol as its major constituent which is known for many pharmacological activities.

Aims:

To evaluate the anti-hyperglycaemic potential of ajwain oil using different in vitro models.

Methods and Material:

In vitro α-amylase and α-glucosidase inhibitory effect of ajwain oil was carried out by the method of Bernfeld and Shibano et al. 1997 with minor modifications respectively. Cytotoxicity of the ajwain oil was assessed using MTT assay. Glucose uptake potential was assessed in differentiated L6 myotubes using fluorescent tagged 6-NBDG.

Results:

Ajwain oil showed very good α – amylase inhibitory activity. A maximum inhibition of 88.55 ±0.43 % was achieved at a concentration of 4µL/ml by ajwain oil which was comparable to that of standard acarbose, 90.96 ± 1.81%. The IC₅₀ of the extract was found to be 0.47µL/ml and for acarbose 0.69µL/ml. The maximum in vitro α – glucosidase inhibitory activity was found to be 89 ± 0.72 % and 91.67 ± 1.09% at 4µL/ml for ajwain oil and acarbose. The IC₅₀ of the extract and acarbose were found to be 0.37µL/ml and 0.41µL/ml respectively. Ajwain oil has enhanced glucose uptake in L6 myotubes in a dose dependent manner.

Conclusion:

The anti-hyperglycaemic activity of the ajwain oil strongly support its ability to decrease sugar level hence it may be further validated for its use as an antidiabetic agent.